SOLIGENIX, INC. (SNGX) - Dilution Analysis

10-Q filing | 14.8M shares outstanding

10-K filing | 10.3M shares outstanding

POS AM filing: This is a POS AM filing with information on expenses of issuance and distribution, indemnification of directors and officers, and shares issuable upon exercise of outstanding warrants.

POS AM filing: This POS AM filing from Soligenix, Inc. on March 31, 2026, relates to the registration of warrant shares being offered by the prospectus. It includes information on expenses of issuance and distribution, indemnification of directors and officers, and the plan of distribution for the common stock.

POS AM filing: This POS AM filing from March 31, 2026, relates to the offering of 4,253 warrant shares.

POS AM filing: This POS AM filing from SNGX details the offering of up to 1,054,688 resale shares of common stock by selling stockholders, with no proceeds to the company.

10-Q filing | 10.1M shares outstanding

8-K filing: Soligenix, Inc. completed a public offering, issuing 4,064,080 shares of common stock, pre-funded warrants to purchase 1,491,480 shares of common stock, and common warrants to purchase 5,555,560 shares of common stock, with gross proceeds of approximately $7.5 million. ($7.5M proceeds)

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.0M shares outstanding

POS AM filing: This is a POS AM filing with information regarding other expenses of issuance and distribution.

POS AM filing: This prospectus relates to the resale from time to time by certain selling stockholders of up to 1,054,688 shares of common stock issuable upon exercise of Warrants.

POS AM filing: This prospectus relates to the offer and sale of 408,640 shares of common stock underlying warrants previously issued by the Company.

10-K filing | 3.2M shares outstanding

10-Q filing | 2.2M shares outstanding

8-K filing: Soligenix, Inc. amended its Loan and Security Agreement with Pontifax Medison Finance to allow the remaining amounts owed under the loan to be satisfied with stock in lieu of cash, reducing the conversion price to $3.81 for the first 501,648 shares and $4.23 for subsequent shares.

10-Q filing | 1.5M shares outstanding

8-K filing: Soligenix, Inc. entered into a warrant inducement agreement with certain holders to exercise existing warrants for cash to purchase up to 703,125 shares of common stock at $6.00 per share, potentially receiving gross proceeds of up to $4,218,750. In consideration, the Company agreed to issue new unregistered warrants to purchase a number of shares equal to 150% of the shares issued upon exercise of the existing warrants. ($4.22M proceeds)

8-K filing: Stock split 1-for-16 | Outstanding: 10,521,233 → 657,577

10-Q filing | 10.5M shares outstanding

8-K filing: Soligenix, Inc. closed a public offering on April 22, 2024, issuing 3,275,000 shares of common stock and pre-funded warrants to purchase 8,600,000 shares, along with common warrants to purchase 11,875,000 shares, for gross proceeds of approximately $4.75 million. ($4.74M proceeds)

S-1/A filing: This S-1/A filing describes an offering of common stock, pre-funded warrants, and common warrants with A.G.P. acting as the exclusive placement agent on a best efforts basis.

S-1/A filing: This S-1/A filing describes an offering of common stock, pre-funded warrants, and common warrants with A.G.P. acting as the exclusive placement agent on a best efforts basis.

10-K filing | 10.4M shares outstanding

S-1 filing: This S-1 filing outlines a proposed offering of common stock, pre-funded warrants, and common warrants underwritten by A.G.P./Alliance Global Partners, with proceeds intended for working capital, corporate procedures, and potential acquisitions.

10-Q filing | 10.4M shares outstanding

S-3 filing: Soligenix, Inc. is offering common stock, preferred stock, warrants, and units up to an aggregate amount of $50,000,000.

10-Q filing | 9.8M shares outstanding

10-Q filing | 2.9M shares outstanding

8-K filing: Soligenix, Inc. closed a public offering on May 9, 2023, selling 2,301,500 shares of common stock and pre-funded warrants to purchase 4,237,000 shares of common stock, along with common warrants to purchase 6,538,500 shares of common stock, for gross proceeds of approximately $8.5 million. ($8.5M proceeds)

S-1/A filing: This S-1/A filing relates to a potential offering of common stock, pre-funded warrants, and common warrants with A.G.P. acting as the exclusive placement agent.

8-K filing: Soligenix, Inc. amended its Director Compensation Policy on May 3, 2023, to increase the number of common stock shares issuable upon exercise of non-qualified stock options granted to directors.

S-1/A filing: This S-1/A filing details information regarding the expenses, indemnification of directors and officers, description of common stock, pre-funded warrants, common warrants, and the plan of distribution related to a securities offering with A.G.P. acting as the exclusive placement agent.

8-K filing: Soligenix, Inc. amended its Loan and Security Agreement with Pontifax Medison Finance, eliminating prepayment penalties, adjusting interest-only payment terms, and reducing the minimum cash covenant. As consideration, the Company repaid $5.0 million of the outstanding principal and reduced the conversion price for the remaining principal amount.

S-1 filing: This S-1 filing relates to a proposed offering of common stock, pre-funded warrants, and common warrants with A.G.P. acting as the exclusive placement agent on a best efforts basis.

10-K filing | 2.9M shares outstanding

10-Q filing | 43.1M shares outstanding

10-Q filing | 43.0M shares outstanding

10-Q filing | 42.9M shares outstanding

10-K filing | 40.1M shares outstanding

10-Q filing | 42.6M shares outstanding

10-Q filing | 40.1M shares outstanding

10-Q filing | 40.1M shares outstanding

10-K filing | 40.0M shares outstanding

S-3 filing: This S-3 filing registers up to 4,878,048 shares of common stock issuable pursuant to the terms of convertible notes, with 31,485,362 shares outstanding as of January 13, 2021.

10-Q filing | 29.8M shares outstanding

10-Q filing | 29.8M shares outstanding

S-3/A filing: Soligenix, Inc. registers an indeterminate number of shares of common stock and preferred stock, warrants to purchase common stock and/or preferred stock, and units consisting of any combination of the foregoing for potential sale, with an aggregate offering price not to exceed $50 million.

S-3/A filing: Soligenix, Inc. is offering common stock, preferred stock, warrants, and units for an aggregate offering price not to exceed $50 million.

S-3 filing: Soligenix, Inc. is offering common stock, preferred stock, warrants, and units up to an aggregate offering price of $50 million.

10-Q filing | 26.6M shares outstanding

10-K filing | 21.8M shares outstanding

8-K filing: Soligenix, Inc. issued 1,956,182 shares of its common stock to Hy Biopharma, Inc. at a price of $2.56 per share, as payment following the achievement of a milestone under the Asset Purchase Agreement.